These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9076901)

  • 1. Influence of the phosphatidylethanolamine (PE) and bovine serum origins on anti-PE antibody detection by ELISA.
    Berard M; Boffa MC
    Thromb Res; 1997 Mar; 85(5):439-42. PubMed ID: 9076901
    [No Abstract]   [Full Text] [Related]  

  • 2. ELISA for antiphosphatidylethanolamine antibody detection: high impact of assay buffer on results.
    Sanmarco M
    J Immunol Methods; 2010 Jun; 358(1-2):9-16. PubMed ID: 20382150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-phosphatidylethanolamine (aPE) antibodies: a survey.
    Mcintyre JA; Wagenknecht DR
    J Autoimmun; 2000 Sep; 15(2):185-93. PubMed ID: 10968907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The outcome of ELISA for antiphosphatidylethanolamine antibodies is dependent on the composition of phosphatidylethanolamine.
    Hou S; Harper PE; Bardin N; Zhao M
    J Immunol Methods; 2017 Jan; 440():27-34. PubMed ID: 27784626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of anti-phosphatidylethanolamine antibodies using flow cytometry.
    Drouvalakis KA; Neeson PJ; Buchanan RR
    Cytometry; 1999 May; 36(1):46-51. PubMed ID: 10331626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex.
    Sugi T; McIntyre JA
    Blood; 1995 Oct; 86(8):3083-9. PubMed ID: 7579402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of Phosphatidylethanolamine Concentration and Composition on the Detection of Antiphosphatidylethanolamine Antibodies by ELISA.
    Ke K; Strango ZI; Harper PE; Zhao M
    J Clin Lab Anal; 2016 Sep; 30(5):689-96. PubMed ID: 27061173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma reactivity to hexagonal II phase phosphatidylethanolamine is more frequently associated with lupus anticoagulant than with antiphosphatidylethanolamine antibodies.
    Berard M; Boffa MC; Karmochkine M; Aillaud MF; Juhan-Vague I; Francès C; Cacoub P; Piette JC; Harlé JR
    J Lab Clin Med; 1993 Nov; 122(5):601-5. PubMed ID: 8228579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antiphosphatidylethanolamine antibody as a marker of antiphospholipid syndrome?].
    Yelnik CM; Dubucquoi S; Houfflin-Debarge V; Lambert M
    Presse Med; 2015 Mar; 44(3):284-91. PubMed ID: 25542711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiphosphatidylethanolamine antibodies and the antiphospholipid syndrome.
    Sanmarco M; Boffa MC
    Lupus; 2009 Sep; 18(10):920-3. PubMed ID: 19671793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiphospholipid antibodies in heart transplant recipients.
    McIntyre JA; Wagenknecht DR; Faulk WP
    Clin Cardiol; 1995 Oct; 18(10):575-80. PubMed ID: 8785903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microtitre plate and assay buffer alter detection of antiphosphatidylethanolamine antibodies in lupus anticoagulant positive plasma.
    Drouvalakis KA; Buchanan RR
    Thromb Res; 1999 May; 94(4):205-12. PubMed ID: 10336235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A sensitive assay for anti-phosphatidylethanol-amine antibody in patients with recurrent fetal loss.
    Hayashi Y; Aoki K; Kunimatsu M; Sasaki M; Yagami Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1990 Nov; 42(11):1565-70. PubMed ID: 2273313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seronegative antiphospholipid syndrome.
    Nayfe R; Uthman I; Aoun J; Saad Aldin E; Merashli M; Khamashta MA
    Rheumatology (Oxford); 2013 Aug; 52(8):1358-67. PubMed ID: 23502076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silvia Pierangeli, PhD (1955-2013).
    Harris EN; Willis R
    Semin Thromb Hemost; 2014 Mar; 40(2):137-9. PubMed ID: 24577999
    [No Abstract]   [Full Text] [Related]  

  • 16. Seronegative Antiphospholipid Syndrome with Anti-phosphatidylethanolamine Antibody in a Boy.
    Asano T; Narazaki H; Kaizu K; Kuwabara K; Fujino O; Itoh Y
    J Nippon Med Sch; 2015; 82(2):117-20. PubMed ID: 25959205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrovascular and neurological disorders associated with antiphospholipid antibodies in CSF and serum.
    Gallo P; Sivieri S; Ferrarini AM; Giometto B; Ruffatti A; Ritter E; Chizzolini C; Tavolato B
    J Neurol Sci; 1994 Mar; 122(1):97-101. PubMed ID: 8195810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical performance (sensitivity and agreement with thrombosis) of four antiphospholipid antibody assays.
    Lopez LR; Whittier AM; Dier KJ; Taylor DO; Buckner TR; Olsen LW; Fink CA
    Am Clin Lab; 2002 Apr; 21(3):41-4. PubMed ID: 12038085
    [No Abstract]   [Full Text] [Related]  

  • 19. Early endosome as a pathogenic target for antiphosphatidylethanolamine antibodies.
    Hou S; Fölsch H; Ke K; Cook Mills J; Ramsey-Goldman R; Zhao M
    Proc Natl Acad Sci U S A; 2017 Dec; 114(52):13798-13803. PubMed ID: 29229837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysophosphatidylethanolamine is the antigen to which apparent antibody to phosphatidylethanolamine binds.
    Qamar T; Gharavi AE; Levy RA; Lockshin MD
    J Clin Immunol; 1990 Jul; 10(4):200-3. PubMed ID: 2211960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.